Miller A B
West J Med. 1988 Dec;149(6):718-22.
Screening has proved effective for only two cancer sites, the breast and the cervix uteri. Only for these, therefore, should screening be a part of routine clinical practice. The degree to which screening is effective depends on whether appropriate groups are screened. For cancer of the breast, current evidence justifies mammographic screening every two years only from the age of 50, continuing at least to the age of 70. The place of breast self-examination and physical examination of the breasts is under investigation, but these procedures should probably be used in all women after the age of 40. For cancer of the cervix, nearly maximal efficacy is obtained by screening sexually active women every three years from the age of 25 to 60. Older women who have not been screened regularly should be screened. Other screening techniques to detect cancers, such as the rectal examination, sigmoidoscopy, and fecal occult blood tests for colorectal cancer, are still experimental. Organizational and other difficulties will prevent screening programs from making a major contribution to reducing overall cancer mortality by the year 2000. If organizational problems can be overcome, however, screening may control invasive cancer of the cervix and make a major contribution in reducing breast cancer mortality in the future.
筛查仅在乳腺癌和子宫颈癌这两个癌症部位被证明是有效的。因此,只有针对这两种癌症,筛查才应成为常规临床实践的一部分。筛查的有效程度取决于是否对合适的人群进行筛查。对于乳腺癌,目前的证据表明,仅从50岁起每两年进行一次乳腺钼靶筛查才是合理的,至少持续到70岁。乳房自我检查和乳房体格检查的作用正在研究中,但这些检查可能应该应用于所有40岁以上的女性。对于子宫颈癌,从25岁至60岁,对有性生活的女性每三年进行一次筛查可获得几乎最大的功效。未定期接受筛查的老年女性也应进行筛查。其他用于检测癌症的筛查技术,如用于结直肠癌的直肠指检、乙状结肠镜检查和粪便潜血试验,仍处于试验阶段。组织方面以及其他方面的困难将阻碍筛查计划在2000年前对降低总体癌症死亡率做出重大贡献。然而,如果能够克服组织问题,筛查可能会控制子宫颈浸润癌,并在未来对降低乳腺癌死亡率做出重大贡献。